CMB International published a research report stating that the US Food and Drug Administration refused to approve evosimab combined chemotherapy for second-line EGFR mutant non-small cell lung cancer, believing that there was no progression, improved survival, but overall survival was not statistically significant, and positive benefit risk characteristics could not be established. The bank said that the full response letter would delay commercialization in the US, and Harmoni-3 and successful combination therapy trials are still at the core of Kang Fang's bioinvestment argument. The bank maintained Kangfang Biotech's “buy” rating and reduced the target price by 28.2% from HK$138.42 to HK$99.34 based on DCF valuation.

Zhitongcaijing · 1d ago
CMB International published a research report stating that the US Food and Drug Administration refused to approve evosimab combined chemotherapy for second-line EGFR mutant non-small cell lung cancer, believing that there was no progression, improved survival, but overall survival was not statistically significant, and positive benefit risk characteristics could not be established. The bank said that the full response letter would delay commercialization in the US, and Harmoni-3 and successful combination therapy trials are still at the core of Kang Fang's bioinvestment argument. The bank maintained Kangfang Biotech's “buy” rating and reduced the target price by 28.2% from HK$138.42 to HK$99.34 based on DCF valuation.